Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7453614 | 0.84 | POLB (0.41) | CHRNB2CHRNA4 | |
| SCHEMBL28824294 | 0.81 | KCNH2 (0.46) | XDHKCNH2SCN5ASCN9ACHRNB2 | |
| SCHEMBL1557265 | 0.81 | LTA4H (0.45) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL29707595 | 0.81 | KCNH2 (0.46) | XDHKCNH2SCN5ASCN9ACHRNB2 | |
| SCHEMBL28824360 | 0.81 | HTT (0.47) | XDHKCNH2SCN5ASCN9AEGFR | |
| SCHEMBL1555903 | 0.81 | LTA4H (0.48) | XDH | |
| SCHEMBL23087878 | 0.81 | LMNA (0.44) | PRMT5WDR77 | |
| SCHEMBL30938621 | 0.81 | SCN9A (0.46) | KCNH2SCN5ASCN9A | |
| SCHEMBL6668822 | 0.79 | LTA4H (0.46) | XDH | |
| SCHEMBL24037638 | 0.78 | NR4A1 (0.40) | SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739307-A2 | TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY | The General Hospital Corporation (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2025010291-A2 | TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY | THE GENERAL HOSPITAL CORPORATION (US) | 2025-01-09 | — | — | WO | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-114533729-A | Glucosylceramide synthase inhibitors | 建新公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2022-03-10 | — | — | US | disclosed |
| EP-2895484-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-108864076-B | Glucosylceramide synthase inhibitors | 建新公司 | 2022-02-11 | — | — | CN | disclosed |
| US-11008316-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2021-05-18 | — | — | US | disclosed |
| CN-101868459-A | Be used for the treatment of diabetes, as the pyridine-2-base-amino-1,2 of glucokinase activating agents, 4-thiadiazoles derivative | ARRAY BIOPHARMA INC | 2010-10-20 | — | — | CN | disclosed |
| US-RE41439-E1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1289996-B1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | TARGACEPT INC (US) | 2005-04-06 | — | — | EP | disclosed |
| CN-1195756-C | Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands | TARGACEPT INC (US) | 2005-04-06 | — | — | CN | disclosed |
| US-6852721-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| CN-1436191-A | Heteroaryl diazabicycloalkanes as nicotinic cholinergic receptor ligands | TARGACEPT INC (US) | 2003-08-13 | — | — | CN | disclosed |
| WO-2001090109-A9 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | TARGACEPT INC (US) | 2003-03-27 | — | — | WO | disclosed |
| EP-1289996-A1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | Targacept, Inc. (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020013309-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2001090109-A1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008316-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GAA | XDH 1832/4885KCNH2 4272/4885SCN5A 2207/4885 |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | XDH 1620/4885KCNH2 3479/4885SCN5A 1227/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | XDH 2078/4885KCNH2 4408/4885SCN5A 2529/4885 |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | XDH 2078/4885KCNH2 4408/4885SCN5A 2529/4885 |
| US-20020013309-A1 | Pharmaceutical compositions and methods for use | CYP2D6, CYP3A5, CYP2B6 | XDH 1443/4885KCNH2 1095/4885SCN5A 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.